Please assess the completion status of the following clinical trial:

Trial Title: Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a 2-year history of seasonal allergic rhinitis~* Has a positive skin test response to a local seasonal allergen (current, or performed in investigator's office within the past year)~* Is in good health and free of any unstable, clinically-significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Women of childbearing potential who are not using an acceptable form of birth control~* Has asthma that requires therapy with inhaled or systemic corticosteroids, cromolyn, or nedocromil~* Has significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal, or other significant medical illness or disorder which, in the judgment of the investigator, could interfere with the study, or required treatment which might interfere with the study~* Is on immunotherapy with the exception of maintenance therapy~* Has a clinically significant upper respiratory or sinus infection~* Has used an investigational drug within the previous 30 days~* Has nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow~* Has a history of multiple drug allergies or an allergy to antihistamines or corticoids~* Has dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines, in the opinion of the investigator~* Has rhinitis medicamentosa~* Is using of any chronic medication which could affect the course of seasonal allergic rhinitis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mometasone furoate nasal spray (Type: EXPERIMENTAL): Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
- placebo nasal spray (Type: PLACEBO_COMPARATOR): Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).